- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about JNJ
Recent news which mentions JNJ
Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program
November 29, 2024
From Benzinga
2 Very Healthy Dividend Stocks to Hold for Decades of Income
November 26, 2024
From Motley Fool
3 Dividend Stocks That Are Screaming Buys in November
November 23, 2024
From Motley Fool
2 Unstoppable Dividend Stocks to Buy Now With $500
November 23, 2024
From Motley Fool
2 Dow Jones Dividend Stocks With Yields Above 3% You Can Buy Now and Hold at Least a Decade
November 23, 2024
From Motley Fool
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
November 21, 2024
Tickers
JNJ
From Benzinga
Price Over Earnings Overview: Johnson & Johnson
November 21, 2024
From Benzinga
This Johnson & Johnson Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
November 15, 2024
From Benzinga
From Benzinga
From Motley Fool
From Benzinga
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
November 08, 2024
From Motley Fool
Industry Comparison: Evaluating Johnson & Johnson Against Competitors In Pharmaceuticals Industry
November 07, 2024
From Benzinga
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
November 06, 2024
From Benzinga
Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
October 28, 2024
From Benzinga
Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease
October 28, 2024
From Benzinga
3 Dividend Growth Stocks You Can Buy and Hold Forever
October 26, 2024
From Motley Fool
Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas
October 25, 2024
From Benzinga
Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry
October 24, 2024
From Benzinga
Meet the Only 2 Game-Changing Businesses With a Higher Credit Rating Than the U.S. Government
October 24, 2024
From Motley Fool
3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime
October 23, 2024
From Motley Fool
From Motley Fool
Justice Department's Trustee Program Alleges Johnson & Johnson's Talc Litigation Bankruptcy Bid Is Bad-Faith Tactic To Avoid Liability
October 22, 2024
From Benzinga
What's Going On With Kenvue Stock Monday?
October 21, 2024
From Benzinga
Tylenol, Listerine Maker Kenvue Under Activist Spotlight With Starboard Value Stake — Overhaul Ahead For The Johnson & Johnson Spinoff?
October 20, 2024
From Benzinga
All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $300 in Passive Income Per Year
October 19, 2024
From Motley Fool
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
October 19, 2024
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.